NCT04148391Active, not recruitingPhase 2
NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)
A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia
Source: ClinicalTrials.gov · Last updated 27 Oct 2022
Brief summary (registry, in English)
A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 99 (actual)
- First submitted
- 30 Oct 2019
- Start date
- 14 Nov 2019
- Primary completion date
- 30 Dec 2022
- Lead sponsor
- Aptinyx
- Diseases
- Lewy body dementia, Parkinson disease
- NCT number
- NCT04148391
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 99
- From 14 Nov 2019 to the primary completion date, 30 Dec 2022
- 23 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current use of medications with primarily central nervous system activities
Other
- Clinically meaningful motor complications
- Other clinically significant medical histories that may interfere with completing the study.
Who the study is looking for
- Informed Consent
- Diagnosis of Parkinson's disease and mild cognitive impairment or mild dementia OR diagnosis of mild cognitive impairment or mild dementia with Lewy bodies
- Presence of subjective cognitive complaints by the patient
- Verifiable impairment, as defined a CGI-S (Clinical Global Impression-Severity) score of at least 3 (mildly ill).
- Score on the MoCA (Montreal Cognitive Assessment) between 15 and 25, inclusive.
- Stable anti-parkinsonian regimen (if applicable)
- Has a study partner who can accompany the subject at specified study visits
Age in the registry: 50 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (23)
Sites in registry order. Pick your city on the disease page to sort them by distance.
This page is information, not medical advice. Discuss any trial with your doctor.